A case of esophageal candidiasis in a psoriatic patient treated with ixekizumab: Should treatment be discontinued?

IL-17A, moderate-to-severe the

[1]  G. Fabbrocini,et al.  Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti‐interleukin‐17 treatment: A real‐life 52‐week retrospective study , 2020, Dermatologic therapy.

[2]  G. Fabbrocini,et al.  Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience , 2020, The Journal of dermatological treatment.

[3]  G. Fabbrocini,et al.  Ixekizumab: An efficacious treatment for both psoriasis and hidradenitis suppurativa , 2020, Dermatologic therapy.

[4]  G. Fabbrocini,et al.  A case of severe psoriasis in a 84‐year‐old women successfully treated with ixekizumab , 2020, Dermatologic therapy.

[5]  G. Fabbrocini,et al.  A case of erythrodermic psoriasis successfully treated with guselkumab , 2019, Dermatologic therapy.

[6]  B. Strober,et al.  Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis , 2017, The British journal of dermatology.

[7]  T. Chiller,et al.  Fungal Infections and New Biologic Therapies , 2016, Current Rheumatology Reports.

[8]  M. Lebwohl,et al.  Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials , 2015, The Lancet.

[9]  A. Puel,et al.  IL-17 and infections. , 2014, Actas dermo-sifiliograficas.

[10]  H. Kang,et al.  Prevalence and Risk Factors of Esophageal Candidiasis in Healthy Individuals: A Single Center Experience in Korea , 2012, Yonsei medical journal.